- PN: B211258
45x Ab-conjugated beads (S4P10 - Mouse EGF Ab-bead).PN: B211258A. One vial containing 100 µL of anti-mouse EGF conjugated to AimPlex Bead S4P10.
25x Biotin-detection Ab (Mouse EGF Biotin-dAb). PN: B211258B. One vial containing 100 µL of biotinylated anti-mouse EGF.
Lyophilized Standard Mix - EGF. PN: B211258S. One vial containing lyophilized recombinant mouse EGF.
STORAGE: 2-8 C in the dark.
IMPORTANT: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.
APPLICATION: Optimal antibody pair and antigen standard for assaying human Mouse EGF. To be used in conjunction with the AimPlex Mouse/Rat Basic Kit (PN: P200201) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.
For Research Use Only. Not for use in diagnostic procedures.
Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate
Sensitivity (LOD): < 10 pgmL
LLOQ: < 20 pg/mL
ULOQ: > 5,000 pg/mL
Standard dose recovery: 70-130%
Intra-assay CV: < 10%
Inter-assay CV: < 20%
Cross-reactivity of analytes in Human Group 3: Negligible
Sample volume: 15 µL/test
Epidermal growth factor or EGF is a growth factor that stimulates cell growth, proliferation, and differentiation by binding to its receptor EGFR. EGF results in cellular proliferation, differentiation, and survival. EGF is found in many human tissues including submandibular gland and the parotid gland. Salivary EGF, which seems also regulated by dietary inorganic iodine, also plays an important physiological role in the maintenance of oro-esophageal and gastric tissue integrity. The biological effects of salivary EGF include healing of oral and gastroesophageal ulcers, inhibition of gastric acid secretion, stimulation of DNA synthesis as well as mucosal protection from intraluminal injurious factors such as gastric acid, bile acids, pepsin, and trypsin and to physical, chemical and bacterial agents. increased activity of the epidermal growth factor receptor (EGFR) has been observed in certain types of cancer, often correlated with mutations in the receptor and abnormal function such as constitutive receptor signaling independent of the levels of EGF or of binding of EGF. EGF and/or EGFR have been exploited to develop imaging methods and targeted therapies against cancers overexpressing EGFR. Diseases associated with EGF include hypomagnesemia 4, renal and hypomagnesemia 6.
1. PDB: 1a3p; Barnham KJ, Torres AM, Alewood D, Alewood PF, Domagala T, Nice EC, Norton RS (August 1998). "Role of the 6-20 disulfide bridge in the structure and activity of epidermal growth factor". Protein Science 7 (8): 1738–49. doi:10.1002/pro.5560070808. PMC 2144085. PMID 10082370.
2. Harris RC, Chung E, Coffey RJ (March 2003). "EGF receptor ligands". Experimental Cell Reseach 284 (1): 2–13. doi:10.1016/S0014-4827(02)00105-2. PMID 12648462.
3. Carpenter G, Cohen S (May 1990). "Epidermal growth factor". The Journal of Biological Chemistry 265 (14): 7709–12. PMID 2186024.
4. Herbst RS (2004). "Review of epidermal growth factor receptor biology". International Journal of Radiation Oncology, Biology, Physics 59 (2 Suppl): 21–6. doi:10.1016/j.ijrobp.2003.11.041. PMID 15142631.Please contact Customer Service at 1-866-618-8932 with any questions or comments.